SEC Form 4 · accession 0001193125-26-271862
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eliyahu Sharon Kalif
Officer — EVP, Chief Financial Officer
Period of report
Jun 11, 2026
Accepted (ET)
Jun 16, 2026 · 8:28 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F3 | Jun 11, 2026 | S | 106,563 | $34.0954 | D | 65,621 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.